Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Metagenomi (NASDAQ:MGX) with a Buy and maintains $7 price target.
Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and lowers the price target from $12 to...
Wells Fargo analyst Yanan Zhu maintains Metagenomi (NASDAQ:MGX) with a Overweight and lowers the price target from $16 to $12.
OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate dea...
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...
